Financial highlights include:
- Total revenues: Q2 2015 of
$126.1 million , up 14% over prior year; six months 2015 of$189.7 million , up 16% over prior year; - GAAP net income/loss: Q2 2015 net income of
$14.1 million , or$0.32 per diluted share; six months 2015 net loss of$7.4 million , or$0.19 per diluted share; - Adjusted net income/loss: Q2 2015 net income of
$17.0 million , or$0.36 per diluted share; six months 2015 net loss of$1.8 million , or$0.05 per diluted share; - EBITDA: Q2 2015 of
$29.6 million , or$0.62 per diluted share; six months 2015 of$9.6 million , or$0.25 per diluted share; and - Adjusted EBITDA: Q2 2015 of
$31.0 million , or$0.65 per diluted share; six months 2015 of$12.2 million , or$0.32 per diluted share.
2015 business accomplishments:
-
FDA approval of Anthrasil™ (Anthrax Immune Globulin Intravenous (Human)) - Awards to manufacture Ebola monoclonal antibodies under our CIADM arrangement with BARDA
- Successful dosing of our first patient in the Phase I trial for MOR209/ES414, our immunotherapeutic treatment for prostate cancer
-
FDA approval and launch of IXINITY®, a recombinant factor IX treatment for Hemophilia B - Continued steady progress on Building 55 sBLA approval
2015 outlook:
- Reaffirmation of previous guidance – FY 2015 total revenues of
$510-$540 million , net income of$50-$60 million (GAAP) and$60-$70 million (adjusted); and - New guidance – Q3 2015 total revenues of
$140 to $155 million .
2015 FINANCIAL PERFORMANCE
(I) Quarter Ended
Revenues
Product Sales
For Q2 2015, product sales were
For full article, please click here.
Help employers find you! Check out all the jobs and post your resume.
